Abs-Medsp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2013-04-04
Share capital
21,900.00 PLN
Registered address
Pileckiego 132/2, 02-781 Warszawa, Poland
Website
Electronic delivery address
AE:PL-33159-20692-AVEAB-13

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2020 – the filing deadline has passed. 2 of 2 financial statements were filed late (the longest delay 210 days for 2019).

  • 2020not filed
  • 201913/05/2021
  • 201819/11/2019
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2019.

Industry · Wholesale of pharmaceutical goods1,033 / 1,549
Top 67%
Division · Wholesale trade17,688 / 29,000
Top 61%
Voivodeship · Mazowieckie60,254 / 142,048
Top 42%
Country · Poland219,065 / 495,934
Top 44%

Results vs industry

Revenue
This companyUSD 270.35kMedianUSD 1.07mAverageUSD 22.39m
Net profit
This companyUSD 21.76kMedianUSD 37.46kAverageUSD 877.59k
Operating costs
This companyUSD 246.10kMedianUSD 932.14kAverageUSD 21.07m
Assets
This companyUSD 107.02kMedianUSD 609.79kAverageUSD 11.84m

Authorized Representatives

Arkadiusz Witold Sieradzkiage 68 – President of the Management Board
Tomasz Michał Sieradzkiage 42 – Vice President of the Management Board

Manner of representation

Each member of the management board represents the company independently.

Ownership

OwnerSharesShare valueStake
146$3,943.8166.6667%
73$1,971.9133.3333%

Arkadiusz Witold Sieradzki and Tomasz Michał Sieradzki hold a combined 100% – the ownership structure indicates family control.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2013-04-11.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$543
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$543
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$543

Competitors

Name
Centrala Farmaceutyczna CefarmS.A.
ITPS.A.
IMC Impomed CentrumS.A.
Gtm-Mobil M-T T.Walisiewiczsp. k.
Reynolds Medicalsp. z o.o.
Petronafsp. z o.o.
CryoprofilS.A.
Novisc Pharmasp. z o.o.
Aimedicalsp. z o.o.
Vorwarts Pharmasp. z o.o.

FAQ

Last updated: 2026-04-26